Biofil Chemicals & Pharmaceuticals share news, announcements and annual reports
NSE: BIOFILCHEMBSE: 524396Pharmaceuticals & BiotechnologySmall Cap
Biofil Chemicals & Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1994 on BSE, Jun 1996 on NSE
Last close ₹28.68down ₹0.73 (2.48%)BSE ₹29.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹29.41.
30 Oct: open ₹29.00, high ₹29.80, low ₹28.26
52-week range of traded prices to 30 Oct 2026
₹25.60Low, 30 Mar 2026₹46.34High, 3 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹47 Cr3,363rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 96.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.16
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 2.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.14
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,71974.4% delivered
Biofil Chemicals & Pharmaceuticals disputes and clarifications
13 filed, newest first.
Feb 2026
3 Feb · Legal
The exchange asked on 3 Feb 2026
Dec 2025
3 Dec · Legal
Nov 2025
26 Nov · Legal
Mar 2024
11 Mar · Legal
Exchange has sought clarification from Biofil Chemicals & Pharmaceuticals Limited with respect to announcement dated 06-Feb-2024, regarding Board meeting held on February 06, 2024.". On basis of above the Company is required to clarify following: 1. The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;2. Date on which the agreement for sale has been entered into;3. The expected date of completion of sale/disposal;4. Consideration received from such sale/disposal;5. Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.6. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";7. Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.The response of the Company is awaited.
Jun 2022
28 Jun · Legal
The exchange asked on 28 Jun 2022
Jul 2021
19 Jul · Legal
The exchange asked on 16 Jul 2021
Apr 2021
30 Apr · Legal
The exchange asked on 29 Apr 2021
Aug 2020
4 Aug · Legal
Exchange has sought clarification from Biofil Chemicals & Pharmaceuticals Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
May 2020
22 May · Legal
The exchange asked on 21 May 2020
Aug 2017
7 Aug · Legal
Exchange has sought clarification from Biofil Chemicals & Pharmaceuticals Limited with respect to announcement dated 04-Aug-2017, regarding "Outcome of Board Meeting held on August 04, 2017." On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.